TY - JOUR
T1 - Glucosamine and chondroitin for knee osteoarthritis : a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens
AU - Fransen, Marlene
AU - Agaliotis, Maria
AU - Nairn, Lillias
AU - Votrubec, Milana
AU - Bridgett, Lisa
AU - Su, Steve
AU - Jan, Stephen
AU - March, Lyn
AU - Edmonds, John
AU - Norton, Robyn
AU - Woodward, Mark
AU - Day, Richard
AU - EGS study collaborative group, null
AU - Buckland-Wright, Chris
AU - Bridges-Webb, Charles
AU - Heritier, Stephane
AU - Jones, Graeme
AU - Sambrook, Phillip
AU - Speechly, Catherine
AU - Vignon, Eric
AU - Jovanovic, Gorica
AU - Jeram, Shila
AU - Dowd, Mitchell
AU - Champion, Mandy
AU - Grealy, Sarah
AU - Watson, Deanne
AU - Vrataric, Anton
AU - Johnson, Cecil
AU - White, Rose
AU - O'Connell, paul
AU - Milwraith, Fay
AU - Kennedy, Danielle
AU - Faulkes, Christine
AU - Bulton, Olivia
AU - Johnson, Kathleen
PY - 2015
Y1 - 2015
N2 - Objective: To determine if the dietary supplements, glucosamine and/or chondroitin, result in reduced joint space narrowing (JSN) and pain among people with symptomatic knee osteoarthritis. Methods: A double-blind randomised placebo-controlled clinical trial with 2-year follow-up. 605 participants, aged 45-75 years, reporting chronic knee pain and with evidence of medial tibio-femoral compartment narrowing (but retaining >2 mm medial joint space width) were randomised to once daily: glucosamine sulfate 1500 mg (n=152), chondroitin sulfate 800 mg (n=151), both dietary supplements (n=151) or matching placebo capsules (n=151). JSN (mm) over 2 years was measured from digitised knee radiographs. Maximum knee pain (0-10) was self-reported in a participant diary for 7 days every 2 months over 1 year. Results: After adjusting for factors associated with structural disease progression (gender, body mass index (BMI), baseline structural disease severity and Heberden's nodes), allocation to the dietary supplement combination (glucosamine-chondroitin) resulted in a statistically significant (p=0.046) reduction of 2-year JSN compared to placebo: mean difference 0.10 mm (95% CI 0.002 mm to 0.20 mm); no significant structural effect for the single treatment allocations was detected. All four allocation groups demonstrated reduced knee pain over the first year, but no significant between-group differences (p=0.93) were detected. 34 (6%) participants reported possibly-related adverse medical events over the 2-year follow-up period. Conclusions: Allocation to the glucosamine-chondroitin combination resulted in a statistically significant reduction in JSN at 2 years. While all allocation groups demonstrated reduced knee pain over the study period, none of the treatment allocation groups demonstrated significant symptomatic benefit above placebo.
AB - Objective: To determine if the dietary supplements, glucosamine and/or chondroitin, result in reduced joint space narrowing (JSN) and pain among people with symptomatic knee osteoarthritis. Methods: A double-blind randomised placebo-controlled clinical trial with 2-year follow-up. 605 participants, aged 45-75 years, reporting chronic knee pain and with evidence of medial tibio-femoral compartment narrowing (but retaining >2 mm medial joint space width) were randomised to once daily: glucosamine sulfate 1500 mg (n=152), chondroitin sulfate 800 mg (n=151), both dietary supplements (n=151) or matching placebo capsules (n=151). JSN (mm) over 2 years was measured from digitised knee radiographs. Maximum knee pain (0-10) was self-reported in a participant diary for 7 days every 2 months over 1 year. Results: After adjusting for factors associated with structural disease progression (gender, body mass index (BMI), baseline structural disease severity and Heberden's nodes), allocation to the dietary supplement combination (glucosamine-chondroitin) resulted in a statistically significant (p=0.046) reduction of 2-year JSN compared to placebo: mean difference 0.10 mm (95% CI 0.002 mm to 0.20 mm); no significant structural effect for the single treatment allocations was detected. All four allocation groups demonstrated reduced knee pain over the first year, but no significant between-group differences (p=0.93) were detected. 34 (6%) participants reported possibly-related adverse medical events over the 2-year follow-up period. Conclusions: Allocation to the glucosamine-chondroitin combination resulted in a statistically significant reduction in JSN at 2 years. While all allocation groups demonstrated reduced knee pain over the study period, none of the treatment allocation groups demonstrated significant symptomatic benefit above placebo.
UR - https://hdl.handle.net/1959.7/uws:75592
U2 - 10.1136/annrheumdis-2013-203954
DO - 10.1136/annrheumdis-2013-203954
M3 - Article
SN - 0003-4967
VL - 74
SP - 851
EP - 858
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 5
ER -